Posted by Michael Wonder on 03 Dec 2022
Orchard Therapeutics announces Swissmedic validation of the marketing authorisation application for Libmeldy (atidarsagene autotemcel)
1 December 2022 - Orchard Therapeutics today announced its marketing authorisation application for Libmeldy (atidarsagene autotemcel) has been accepted for evaluation by Swissmedic for the potential treatment of eligible patients with early-onset metachromatic leukodystrophy.
The Swiss filing was based on the European Union marketing authorisation application for Libmeldy, which was approved by the European Commission in December 2020.
